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Submitted Sep 11, 2013; accepted Oct 17, 2013.DISCUSSIONDr Larry Kraiss (Salt Lake City, Utah). Congratulations to
Ms Chong who very ably presented this paper. I also thank the
authors for a timely submission of their paper for my review.
The UCSF group is to be commended for reminding us that
PAD is in reality a systemic disease. They report that self-reported
walking impairment correlates best with objectively measured end-
othelial function, which is a systemic condition as opposed to the
ABI, which might be considered a limb-speciﬁc condition. Walking
impairment is an endpoint that is sensitive to many factors, only one
of which is the ABI or the degree of hemodynamic impairment that
the limb experiences. Also, I think we have all had patients who
underwent intervention for claudication with an improvement in
ABI but a disappointing response in walking distance. So, this partic-
ular conclusion, on its face, is not too difﬁcult to accept, but I do
have some reservations about the data supporting this conclusion.First, although the study population is extensively phenotyped
in terms of endothelial function, ABI, and multiple biochemical
parameters, the clinical characterization is suboptimal. As we
have heard before during this meeting, the venerable Rutherford
classiﬁcation has probably outlived its usefulness, so I question
the accuracy of self-reported walking distance in terms of “blocks.”
There is no information about whether these self-reported
outcomes are accurate or reproducible. Your study would be greatly
strengthened by an objective measure of walking impairment, such
as the 6-minute walk test. While the authors acknowledge this limi-
tation, it remains a major drawback to the study’s impact.
Ms Karen Chong.We acknowledge this as a limitation of our
study. We are therefore excited to launch our trial that will have
a 6-minute walk test as an outcome in addition to self-reported
Rutherford and the WIQ.
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1034 Grenon et al April 2014Dr Kraiss. Second, the authors report that endothelial func-
tion as measured by brachial artery FMD is the only parameter
that correlates with severity of claudication classiﬁed by Rutherford
category. However, in the manuscript, there is a 100% overlap
between endothelial function scores for group II compared to
group III. This challenges my statistical “smell” test.
Finally, the authors report that endothelial function did not
correlate with ABI but the P value for this relationship is .21. So,
there is an 80% chance that ABI and endothelial function really do
correlate. Since there are so few subjects in the Rutherford class I
and II categories, I wonder if it is really true that ABI and endothelial
function do not correlate or whether this is in essence a type II error.
These are issues that I will let the authors address in the JVS
editorial process, as I am not sure that a discussion around these
points will be all that informative this morning. I do have four
straightforward questions for the authors:
1. How were patients selected for the study? Were they consec-
utive? Were they new or established patients, or both?
2. Did inﬂow or outﬂow location of disease correlate with endo-
thelial function?
3. Had any patients in the study received previous treatment
directed at claudication?
4. Have any of the study patients subsequently received treat-
ment for claudication? If so, did endothelial function predict
treatment outcome?This is a worthwhile area of study and I encourage the authors
to continue their investigations. I suspect that they are on to some-
thing that may ultimately help us better select claudicants who will
beneﬁt the most from intervention.
Ms Chong. To answer your questions:
1. We essentially attempted to recruit any patient that came
through our clinic with PAD, provided that they ﬁt our eligi-
bility criteria and provided consent. This included both new
and established patients.
2. We have not yet looked at the location of the disease, but that
is actually the next direction for us. We plan to look at angio-
graphic or MR imaging to determine location of lesions and
quantity of collaterals to see if these factors might correlate
with endothelial function or walking disability.
3. There were patients that had prior revascularization, but this
was the minority. In those cases, we based our clinical Ruther-
ford category on their symptoms prior to any revascularization
to ensure that their native symptoms would be captured.
4. Study patients certainly have subsequently received treatment
for claudication. However, we have not collected these data,
but we do have access to it. It would be interesting to see if
endothelial function does predict treatment outcome. For
now, our lab, the Vascular Integrated Physiology and Experi-
mental Therapeutics Lab (VIPERx), is focusing on establish-
ing a modiﬁable risk factor in patients with claudication.
